News & Updates

Increased serum concentration of 25(OH)D appears to contribute to a reduced risk of type 2 diabetes (T2D) across the glycaemic spectrum below the threshold for diabetes, reports a study. Improving the lipid profile may be partly responsible for the favourable association.

Initiation of sodium-glucose cotransporter-2 (SGLT-2) inhibitors results in a 35-percent reduced risk of dementia compared with dipeptidyl peptidase-4 (DPP-4) inhibitors in individuals with type 2 diabetes (T2D) aged 40–69 years, according to a study. In addition, greater benefits are seen with longer treatment duration.

Data from the Hong Kong Childhood Diabetes Registry (HKCDR) show that 2 years after diagnosis of paediatric type 2 diabetes mellitus (T2DM), approximately 20–65 percent of patients have ≥1 of the following: microalbuminuria (MA), suboptimal glycaemic control, hypertension, or dyslipidaemia.

A strong, positive link between BMI and the risk of colorectal cancer (CRC) incidence and related deaths has been found in Asian populations.

Empagliflozin significantly reduces hepatic fat content vs placebo in patients with metabolic dysfunction–associated steatotic liver disease (MASLD) without diabetes, researchers from the University of Hong Kong have reported.